Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Identifying Plasma Derived Extracellular Vesicle (EV) Contained Biomarkers in the Development of Chronic Neuropathic Pain.

Sosanya NM, Kumar R, Clifford JL, Chavez R, Dimitrov G, Srinivasan S, Gautam A, Trevino AV, Williams M, Hammamieh R, Cheppudira BP, Christy RJ, Crimmins SL.

J Pain. 2019 Jun 19. pii: S1526-5900(18)30775-2. doi: 10.1016/j.jpain.2019.05.015. [Epub ahead of print]

PMID:
31228575
2.

Functional Heatmap: an automated and interactive pattern recognition tool to integrate time with multi-omics assays.

Williams JR, Yang R, Clifford JL, Watson D, Campbell R, Getnet D, Kumar R, Hammamieh R, Jett M.

BMC Bioinformatics. 2019 Feb 15;20(1):81. doi: 10.1186/s12859-019-2657-0.

3.

Antinociceptive effects of pluronic lecithin organo (PLO)-opioid gels in rats with thermal injury.

Clifford JL, Christy RJ, Cheppudira BP.

Burns. 2017 Dec;43(8):1709-1716. doi: 10.1016/j.burns.2017.04.020. Epub 2017 Aug 1.

PMID:
28778760
4.

Local Resiniferatoxin Induces Long-Lasting Analgesia in a Rat Model of Full Thickness Thermal Injury.

Salas MM, Clifford JL, Hayden JR, Iadarola MJ, Averitt DL.

Pain Med. 2017 Dec 1;18(12):2453-2465. doi: 10.1093/pm/pnw260.

5.

Anti-nerve growth factor antibody attenuates chronic morphine treatment-induced tolerance in the rat.

Cheppudira BP, Trevino AV, Petz LN, Christy RJ, Clifford JL.

BMC Anesthesiol. 2016 Sep 5;16(1):73. doi: 10.1186/s12871-016-0242-x.

6.

Progress of clinical practice on the management of burn-associated pain: Lessons from animal models.

McIntyre MK, Clifford JL, Maani CV, Burmeister DM.

Burns. 2016 Sep;42(6):1161-72. doi: 10.1016/j.burns.2016.01.023. Epub 2016 Feb 20. Review.

PMID:
26906668
7.

Preemptive perineural bupivacaine attenuates the maintenance of mechanical and cold allodynia in a rat spinal nerve ligation model.

Clifford JL, Mares A, Hansen J, Averitt DL.

BMC Anesthesiol. 2015 Oct 6;15:135. doi: 10.1186/s12871-015-0113-x.

8.

Tetrodotoxin suppresses thermal hyperalgesia and mechanical allodynia in a rat full thickness thermal injury pain model.

Salas MM, McIntyre MK, Petz LN, Korz W, Wong D, Clifford JL.

Neurosci Lett. 2015 Oct 21;607:108-113. doi: 10.1016/j.neulet.2015.09.031. Epub 2015 Sep 28.

9.

Anti-hyperalgesic effects of AG490, a Janus kinase inhibitor, in a rat model of inflammatory pain.

Cheppudira BP, Garza TH, Petz LN, Clifford JL, Fowler M.

Biomed Rep. 2015 Sep;3(5):703-706. Epub 2015 Jul 27.

10.

Biological activities of fusarochromanone: a potent anti-cancer agent.

Mahdavian E, Palyok P, Adelmund S, Williams-Hart T, Furmanski BD, Kim YJ, Gu Y, Barzegar M, Wu Y, Bhinge KN, Kolluru GK, Quick Q, Liu YY, Kevil CG, Salvatore BA, Huang S, Clifford JL.

BMC Res Notes. 2014 Sep 3;7:601. doi: 10.1186/1756-0500-7-601.

11.

State of the science review: Advances in pain management in wounded service members over a decade at war.

Clifford JL, Fowler M, Hansen JJ, Cheppudira B, Nyland JE, Salas MM, McGhee LL, Petz LN, Loyd DR.

J Trauma Acute Care Surg. 2014 Sep;77(3 Suppl 2):S228-36. doi: 10.1097/TA.0000000000000403. Review.

PMID:
25159359
12.

A rat model of full thickness thermal injury characterized by thermal hyperalgesia, mechanical allodynia, pronociceptive peptide release and tramadol analgesia.

Fowler M, Clifford JL, Garza TH, Slater TM, Arizpe HM, Novak J, Petz LN, Loyd DR.

Burns. 2014 Jun;40(4):759-71. doi: 10.1016/j.burns.2013.10.011. Epub 2013 Nov 26.

PMID:
24290856
13.

Curcumin: a novel therapeutic for burn pain and wound healing.

Cheppudira B, Fowler M, McGhee L, Greer A, Mares A, Petz L, Devore D, Loyd DR, Clifford JL.

Expert Opin Investig Drugs. 2013 Oct;22(10):1295-303. doi: 10.1517/13543784.2013.825249. Epub 2013 Aug 1. Review.

PMID:
23902423
14.

Topical curcumin-based cream is equivalent to dietary curcumin in a skin cancer model.

Sonavane K, Phillips J, Ekshyyan O, Moore-Medlin T, Roberts Gill J, Rong X, Lakshmaiah RR, Abreo F, Boudreaux D, Clifford JL, Nathan CA.

J Skin Cancer. 2012;2012:147863. doi: 10.1155/2012/147863. Epub 2012 Dec 13.

15.

Effects of the tropical ginger compound,1'-acetoxychavicol acetate, against tumor promotion in K5.Stat3C transgenic mice.

Batra V, Syed Z, Gill JN, Coburn MA, Adegboyega P, DiGiovanni J, Mathis JM, Shi R, Clifford JL, Kleiner-Hancock HE.

J Exp Clin Cancer Res. 2012 Jun 15;31:57. doi: 10.1186/1756-9966-31-57.

16.

HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop.

Syed ZA, Yin W, Hughes K, Gill JN, Shi R, Clifford JL.

BMC Cancer. 2011 May 19;11:180. doi: 10.1186/1471-2407-11-180.

17.

Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo.

Phillips JM, Clark C, Herman-Ferdinandez L, Moore-Medlin T, Rong X, Gill JR, Clifford JL, Abreo F, Nathan CO.

Otolaryngol Head Neck Surg. 2011 Jul;145(1):58-63. doi: 10.1177/0194599811400711.

PMID:
21493306
18.

System level changes in gene expression in maturing bladder mucosa.

Dozmorov M, Stone R 2nd, Clifford JL, Sabichi AL, Engles CD, Hauser PJ, Culkin DJ, Hurst RE.

J Urol. 2011 May;185(5):1952-8. doi: 10.1016/j.juro.2010.12.101. Epub 2011 Mar 21.

19.

Role of α6β4 integrin in cell motility, invasion and metastasis of mammary tumors.

Soung YH, Gil HJ, Clifford JL, Chung J.

Curr Protein Pept Sci. 2011 Feb;12(1):23-9. Review.

PMID:
21190525
20.

Effects of ATRA combined with citrus and ginger-derived compounds in human SCC xenografts.

Kleiner-Hancock HE, Shi R, Remeika A, Robbins D, Prince M, Gill JN, Syed Z, Adegboyega P, Mathis JM, Clifford JL.

BMC Cancer. 2010 Jul 26;10:394. doi: 10.1186/1471-2407-10-394.

21.

Crosstalk between integrin and receptor tyrosine kinase signaling in breast carcinoma progression.

Soung YH, Clifford JL, Chung J.

BMB Rep. 2010 May;43(5):311-8. Review.

22.

Identification of genes correlated with early-stage bladder cancer progression.

Stone R 2nd, Sabichi AL, Gill J, Lee IL, Adegboyega P, Dai MS, Loganantharaj R, Trutschl M, Cvek U, Clifford JL.

Cancer Prev Res (Phila). 2010 Jun;3(6):776-86. doi: 10.1158/1940-6207.CAPR-09-0189. Epub 2010 May 25.

23.

The promise of natural products for blocking early events in skin carcinogenesis.

Clifford JL, DiGiovanni J.

Cancer Prev Res (Phila). 2010 Feb;3(2):132-5. doi: 10.1158/1940-6207.CAPR-09-0267. Epub 2010 Jan 26. Review.

24.

All-trans retinoic acid suppresses Stat3 signaling during skin carcinogenesis.

Syed Z, Cheepala SB, Gill JN, Stein J, Nathan C, Digiovanni J, Batra V, Adegboyega P, Kleiner HE, Clifford JL.

Cancer Prev Res (Phila). 2009 Oct;2(10):903-11. doi: 10.1158/1940-6207.CAPR-09-0041. Epub 2009 Sep 29.

25.

Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion.

Cheepala SB, Yin W, Syed Z, Gill JN, McMillian A, Kleiner HE, Lynch M, Loganantharaj R, Trutschl M, Cvek U, Clifford JL.

Mol Cancer. 2009 May 11;8:27. doi: 10.1186/1476-4598-8-27.

26.

Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis.

Kataoka K, Kim DJ, Carbajal S, Clifford JL, DiGiovanni J.

Carcinogenesis. 2008 Jun;29(6):1108-14. doi: 10.1093/carcin/bgn061. Epub 2008 May 2.

27.

Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.

Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM.

Clin Cancer Res. 2008 Jan 1;14(1):224-9. doi: 10.1158/1078-0432.CCR-07-0733.

28.

Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene.

Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D, Lotan R.

J Natl Cancer Inst. 2007 Nov 21;99(22):1668-82. Epub 2007 Nov 13.

PMID:
18000218
29.

Retinoids and skin: microarrays shed new light on chemopreventive action of all-trans retinoic acid.

Cheepala SB, Syed Z, Trutschl M, Cvek U, Clifford JL.

Mol Carcinog. 2007 Aug;46(8):634-9. Review.

PMID:
17538947
30.

Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.

Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM.

J Clin Oncol. 2007 May 20;25(15):1974-8.

PMID:
17513803
31.

Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions.

Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J, Clifford JL.

Mol Cancer. 2006 Apr 7;5:15.

32.

Identification and characterization of the human retinoid X receptor alpha gene promoter.

Li G, Yin W, Chamberlain R, Hewett-Emmett D, Roberts JN, Yang X, Lippman SM, Clifford JL.

Gene. 2006 May 10;372:118-27. Epub 2006 Mar 6.

PMID:
16517099
33.

Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.

Xu H, Cheepala S, McCauley E, Coombes K, Xiao L, Fischer SM, Clifford JL.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):969-79.

34.

Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM.

Yin W, Rossin A, Clifford JL, Gronemeyer H.

Oncogene. 2006 Jun 22;25(26):3735-44. Epub 2006 Jan 30.

PMID:
16449964
35.

Identification of a novel splice variant of X-linked inhibitor of apoptosis-associated factor 1.

Yin W, Cheepala S, Clifford JL.

Biochem Biophys Res Commun. 2006 Jan 27;339(4):1148-54. Epub 2005 Dec 5.

PMID:
16343440
36.

Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.

Sabichi AL, Xu H, Fischer S, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Clifford JL.

Clin Cancer Res. 2003 Oct 1;9(12):4606-13.

37.

Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei.

Salas TR, Reddy SA, Clifford JL, Davis RJ, Kikuchi A, Lippman SM, Menter DG.

J Biol Chem. 2003 Oct 17;278(42):41338-46. Epub 2003 Aug 4.

39.

Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis.

Clifford JL, Walch E, Yang X, Xu X, Alberts DS, Clayman GL, El-Naggar AK, Lotan R, Lippman SM.

Clin Cancer Res. 2002 Jul;8(7):2067-72.

40.

Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.

Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM.

J Clin Oncol. 2002 Jan 15;20(2):364-70.

PMID:
11786562
41.

Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer.

Clifford JL, Sabichi AL, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Lippman SM.

Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):391-5.

42.

Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin.

Clifford JL, Menter DG, Yang X, Walch E, Zou C, Clayman GL, Schaefer TS, El-Naggar AK, Lotan R, Lippman SM.

Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):993-7.

43.

Stress pathway activation induces phosphorylation of retinoid X receptor.

Lee HY, Suh YA, Robinson MJ, Clifford JL, Hong WK, Woodgett JR, Cobb MH, Mangelsdorf DJ, Kurie JM.

J Biol Chem. 2000 Oct 13;275(41):32193-9.

44.

Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis.

Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P.

J Biol Chem. 2000 Oct 27;275(43):33607-13.

45.

Cloning and characterization of the human retinoid X receptor alpha gene: conservation of structure with the mouse homolog.

Li G, Walch E, Yang X, Lippman SM, Clifford JL.

Biochem Biophys Res Commun. 2000 Mar 5;269(1):54-7.

PMID:
10694476
46.

Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells.

Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM.

Cancer Res. 1999 Jan 1;59(1):14-8.

47.
48.
49.

Nuclear receptors for retinoids: mediators of retinoid effects on normal and malignant cells.

Lotan R, Clifford JL.

Biomed Pharmacother. 1991;45(4-5):145-56. Review.

PMID:
1657236
50.

Modulation by retinoids of mRNA levels for nuclear retinoic acid receptors in murine melanoma cells.

Clifford JL, Petkovich M, Chambon P, Lotan R.

Mol Endocrinol. 1990 Oct;4(10):1546-55.

PMID:
2178220

Supplemental Content

Loading ...
Support Center